xDRIVE Functional Precision Medicine and Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients with Relapsed or Refractory Cancers

What this Trial Is About

Researchers are evaluating the feasibility of providing the xDRIVE Functional Precision Medicine and Artificial Intelligence platform to cancer patients across Florida, especially those from underserved groups such as pediatric patients and minorities. This study aims to assess patient clinical benefit and health economic impacts by offering personalized cancer treatment support to patients with relapsed or refractory cancers. The program builds on previous promising results demonstrating actionable treatment recommendations and improved progression-free survival in pediatric patients with aggressive cancers. Participants in this single-arm feasibility study will undergo tumor profiling using the xDRIVE platform. This platform analyzes tumor samples to generate individualized treatment recommendations, which are returned to the treating physician within two weeks and may be used to guide the patient's next line of therapy. The study includes both pediatric and adult patients who have relapsed or refractory cancers and have received prior standard therapy. Blood or buccal swab samples will also be collected for matched normal DNA comparison during profiling. During the study, patients will provide tumor tissue through biopsy, excision, or resection, and treatment and outcome information from prior therapies. The research team will review progression-free survival, objective response rate, and disease control rate one year after enrollment. The study focuses on monitoring the return of treatment recommendations within a clinically actionable timeframe and gathering data on clinical benefit and health economics. Participation includes blood draws or swabs and clinical follow-up as needed, with the total study duration varying by patient.

xDRIVE for Florida-based Cancer Patients